Skip to main content
INSMED Inc logo

INSMED Inc — Investor Relations & Filings

Ticker · INSM ISIN · US4576693075 LEI · 529900Q55QAG41CCAC11 US Manufacturing
Open in API
Filings indexed 1,323 across all filing types
Latest filing 2020-11-07 Director's Dealing
Country US United States of America
Listing US INSM

About INSMED Inc

https://insmed.com/

Insmed Incorporated is a global biopharmaceutical company dedicated to developing and commercializing therapies for patients with serious and rare diseases. The company's primary focus is on addressing areas of high unmet medical need. Its marketed product, Arikayce (liposomal amikacin for inhalation), is a treatment for Mycobacterium avium complex (MAC) lung disease. Insmed leverages proprietary technologies, such as its advanced liposomal pulmonary delivery system, to create novel treatments. The company maintains a diverse pipeline of investigational medicines and is actively advancing potential new therapies through various stages of clinical trials.

Recent filings

Filing Released Lang Actions
4
Director's Dealing
2020-11-07 English
4
Director's Dealing
2020-11-06 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text specifically mentions Item 2.02, which relates to "Results of Operations and Financial Condition," and references a press release containing financial results for the three and nine months ended September 30, 2020. The document itself does not contain detailed financial statements or substantive financial data but rather furnishes a press release as an exhibit. The length of the document is 3732 characters, which is relatively short and consistent with an announcement rather than a full financial report. According to the rules, such a document is best classified as a Regulatory Filing (RNS) because it is a current report announcing financial results but does not contain the full financial report or detailed analysis itself. It is not an Earnings Release (ER) because the actual financial results are in the press release exhibit, and the 8-K is a filing form. Therefore, the appropriate classification is Regulatory Filings (RNS).
2020-10-29 English
10-Q
Interim / Quarterly Report Q3 2020
2020-10-29 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text includes a press release about the European Commission granting marketing authorization for a drug, which is an event disclosure. The document is short (4179 characters) and primarily serves as an announcement rather than a detailed financial report or earnings release. It does not contain financial statements or detailed financial analysis. Therefore, it fits the category of a Regulatory Filing (RNS), which is a general category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-10-28 English
JANUS HENDERSON GROUP PLC OWNS 6.1% OF INSMED
Major Shareholding Notification
2020-10-09 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.